Olivier Rosmorduc

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle et al. · The Lancet · 2016 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +8

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy

Olivier Chazouillères, Dominique Wendum, Lawrence Serfaty et al. · Hepatology · 1998 · 753 citations

Medicine, Internal Medicine, Pathology +17

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Thomas Yau, J.W. Park, Richard S. Finn et al. · Annals of Oncology · 2019 · 648 citations · Full text

Medicine, Oncology, Pharmacology +12

SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans et al. · Journal of Clinical Oncology · 2014 · 577 citations · Full text

Medicine, Oncology, Pharmacotherapy +12